![](https://media.americanpharmaceuticalreview.com/m/28/article/613972.jpg)
Perrigo Completes Divestment of HRA Pharma Rare Diseases Business
Perrigo Company announced that it has completed the previously announced divestment of the HRA Pharma Rare Diseases business to Esteve Healthcare, S.L. for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million, …